Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04659044 · ClinicalTrials.gov registry record · Phase 2
Polatuzumab Vedotin, Venetoclax, and Rituximab and Hyaluronidase Human for the Treatment of Relapsed or Refractory Mantle Cell Lymphoma
A Phase 2 study, sponsored by Academic and Community Cancer Research United.
- Terminated
- Registry status
- Phase 2
- Development phase
- 3
- Enrollment target
NCT04659044 is a Phase 2 study that was terminated before completion, run by Academic and Community Cancer Research United. The registered enrollment target is 3 participants.
The verdict
NCT04659044, a Phase 2 study, was terminated before completion, sponsored by Academic and Community Cancer Research United.
- TERMINATED
- Registry status
- Phase 2
- Development phase
- 3 participants
- Enrollment target
Study Summary
This phase II trial studies the effect of polatuzumab vedotin, venetoclax, and rituximab and hyaluronidase human in treating patients with mantle cell lymphoma that has come back (relapsed) or does not respond to treatment (refractory). Polatuzumab vedotin is a monoclonal antibody, polatuzumab, linked to a toxic agent called vedotin. Polatuzumab attaches to CD79B positive cancer cells in a targeted way and delivers vedotin to kill them. Venetoclax may stop the growth of cancer cells by blocking Bcl-2, a protein needed for cell growth. Rituximab hyaluronidase is a combination of rituximab and hyaluronidase. Rituximab binds to a molecule called CD20, which is found on B cells (a type of white blood cell) and some types of cancer cells. This may help the immune system kill cancer cells. Hyaluronidase allows rituximab to be given by injection under the skin. Giving rituximab and hyaluronidase by injection under the skin is faster than giving rituximab alone by infusion into the blood. Giving polatuzumab vedotin, venetoclax, and rituximab and hyaluronidase human may work better than standard therapy in treating patients with mantle cell lymphoma.
Interventions
- DRUG Venetoclax
- BIOLOGICAL Rituximab
- DRUG Polatuzumab Vedotin
- BIOLOGICAL Rituximab and Hyaluronidase Human
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 3 participants |
| Start Date | 2021-04-01 |
| Est. Completion | 2024-03-29 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04659044
The ClinicalTrials.gov registry entry for NCT04659044 describes a study currently listed as terminated, categorized as Phase 2. The registered enrollment target is 3 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Academic and Community Cancer Research United, which has 42 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 4 interventions - of which Venetoclax is the first listed.
NCT04659044 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT04659044 about?
NCT04659044 is a clinical study titled "Polatuzumab Vedotin, Venetoclax, and Rituximab and Hyaluronidase Human for the Treatment of Relapsed or Refractory Mantle Cell Lymphoma". This phase II trial studies the effect of polatuzumab vedotin, venetoclax, and rituximab and hyaluronidase human in treating patients with mantle cell lymphoma that has come back (relapsed) or does not respond to treatment (refractory). Polatuzumab vedotin is a monoclonal antibody, polatuzumab, link...
What is the current status of trial NCT04659044?
This trial is currently terminated. It is a Phase 2 study. The enrollment target is 3 participants. The study started on 2021-04-01. Estimated completion is 2024-03-29.
What interventions are being tested in trial NCT04659044?
The interventions under investigation include: Venetoclax (DRUG), Rituximab (BIOLOGICAL), Polatuzumab Vedotin (DRUG), Rituximab and Hyaluronidase Human (BIOLOGICAL).
Who is sponsoring clinical trial NCT04659044?
This trial is sponsored by Academic and Community Cancer Research United, which has 42 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.